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Résumé en
anglais
The toxicity of second-generation antihistamines after an overdose by a child is still
unknown. The objective of this study is to use data from Poisons Centres in France to
describe the toxicity profile of second-generation antihistamines for children and to
compare the severity of poisoning observed from these with a first-generation
antihistamine. This was a retrospective, multi-centre and observational study focusing
on human cases of single-substance exposure to a second-generation antihistamine and
to mequitazine, reported between 1 January 2001 and 31 December 2016 in Poisons
Centres in France. From a total of 9403 children included, 5980 were exposed to a
second-generation antihistamine and 3423 were exposed to mequitazine. The severity
of exposure to second-generation antihistamines in children is low: among the children
followed until a known outcome, 9% of children were symptomatic and in 97% of cases,
the symptoms shown were of a minor-level severity (primarily drowsiness or
restlessness). Depending on the substance, children who ingested doses 16 to 69 times
the maximum recommended therapeutic dose remained asymptomatic. No deaths or
severe symptoms were observed. No cases of lengthening of the QT interval or
arrhythmias were identified. Mequitazine led to more symptoms than other substances
(14.8% symptomatic children vs. 7.5%, Odd ratio (OR): 2.3 (2.0-2.6), p < 0.0001), more
symptoms of moderate intensity (1.4 vs. 0.2%, OR: 8.3 (4.1-18.5), p < 0.0001) and more
hospitalisation (19.1 vs. 8.7%, OR: 2.5, 95% CI: (2.2-2.8), p < 0.0001). The severity of
poisoning from second-generation antihistamines appears to be low among children
and considerably lower than poisoning caused by mequitazine.
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